Press Releases

Results Found (124)
February 12, 2008
MORRIA BIOPHARMACEUTICALS PLC ANNOUNCES PRELIMINARY SAFETY AND TOLERABILITY...

Yissum spin-off Morria Biopharmaceuticals, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients...

January 8, 2008
YISSUM AND EUCALYPTUS SIGN LICENSING AGREEMENT FOR THE DEVELOPMENT OF A...

Molecule is an antioxidant that overcomes the blood-brain barrier

December 25, 2007
YISSUM LICENSES ANTI-CANCER COMPOUND BL-4060 TO BIOLINERX

Yissum and BioLineRx signed a worldwide exclusive license agreement for the development and commercialization of BL-4060, a small molecule drug candidate for the treatment of cancer.

December 25, 2007
YISSUM SPINS-OFF NANOLYMF TO ADVANCE BREAKTHROUGH LIVER-BYPASSING ORAL DRUG...

Yissum announced the formation of Nanolymf, a biotechnology start up company dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs.

November 6, 2007
BELGIAN CO LICENSES HEBREW U BIODEGRADABLE PLASTIC

Yissum Technology Transfer Company of the Hebrew University of Jerusalem has signed a new licensing agreement with a Belgian holding company for the commercialization of a new clean technology developed at the university.

October 31, 2007
YISSUM PRESENTS AT WATEC 2007 A NEW ENVIRONMENTALLY-FRIENDLY METHOD FOR THE...
October 29, 2007
YISSUM'S SPIN-OFF EIN GIBTON SUCCEEDS IN A WATER PURIFICATION EXPERIMENT
October 28, 2007
YISSUM PRESENTS AT WATEC 2007 A NEW ENVIRONMENTALLY-FRIENDLY METHOD FOR THE...

A research group headed by Hebrew University Professor Aaron Kaplan found a solution to the growing problem of toxic algae

October 26, 2007
HUJI RESEARCHERS DEVELOP A NEW SYSTEM FOR THE IDENTIFICATION OF PLANTS...
August 15, 2007
A NEW CONSORTIUM IN THE WATER CLEANTECH FIELD INITIATED BY YISSUM AND THE...

The OCS authorized the three-year budget, with 15M NIS secured for the first year

August 12, 2007
YISSUM AND PROTALIX BIOTHERAPEUTICS SIGN AGREEMENT TO LICENSE...

Protalix BioTherapeutics to Explore Biodefense and Civilian Applications with Researchers from Hebrew University of Jerusalem

August 4, 2007
TEVA BUYS ASTHMA TREATMENT RIGHTS FROM YISSUM (HEBREW)

The treatment was found in testing to have eliminated four different types of allergic diseases in mice.